Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EGFR mutation

- PMLiVE

AZ shutters R&D unit in India

Local reports says pharma company will transfer operations to UK and outsourcing partners

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

AZ’s Soriot upbeat on firm’s prospects

Says pharma company can return to growth by 2017

- PMLiVE

GSK ends muscular dystrophy deal

Terminates rare disease collaboration with Prosensa after trial disappointment

- PMLiVE

2013 – biotech boomed

The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links